Results 21 to 30 of about 763,886 (286)

Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults [PDF]

Case Reports in Oncological Medicine, 2013
MYCN is a well-known oncogene overexpressed in different human malignancies including neuroblastoma, rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms’ tumor, and small cell lung cancer.
Anna Koumarianou, Panagiota Oikonomopoulou, Margarita Baka, Dimitrios Vlachodimitropoulos, Stylianos Argentos, Theodoros Piperos, Maria-Ioanna Christodoulou, Kakoulis Theodoulou, Theodoros Mariolis-Sapsakos   +8 more
doaj   +2 more sources

Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2004
The mechanisms causing persistence of embryonal cells that later give rise to tumors is unknown. One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene. Here we show that normal mice developed neuroblast hyperplasia in paravertebral ganglia at birth that completely regressed ...
Loen M. Hansford, Wayne Thomas, Joanna Keating, Catherine A. Burkhart, Anne E. Peaston, Murray D. Norris, Michelle Haber, Patricia J. Armati, William A. Weiss, Glenn M. Marshall   +9 more
openalex   +4 more sources

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification. [PDF]

Medicine (Baltimore), 2020
Neuroblastoma (NB) with MYCN amplification has a poor prognosis and high mortality. The potential molecular biological relationship between clinical features and MYCN amplification should be explored.NB patients were examined by fluorescence in situ hybridization (FISH) for MYCN amplification in the tumor mass or bone marrow samples to determine ...
Huang C, Jiang S, Yang J, Liao X, Li Y, Li S.   +5 more
europepmc   +4 more sources

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status. [PDF]

Int J Mol Sci, 2020
Transglutaminase 2 (TG2) is a multifunctional enzyme and two isoforms, TG2-L and TG2-S, exerting opposite effects in the regulation of cell death and survival, have been revealed in cancer tissues.
Currò M, Ferlazzo N, Giunta ML, Montalto AS, Russo T, Arena S, Impellizzeri P, Caccamo D, Romeo C, Ientile R.   +9 more
europepmc   +2 more sources

Regulation of MYCN expression in human neuroblastoma cells [PDF]

BMC Cancer, 2009
Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I, Hulsbergen-van de Kaa Christina A, van Leeuwen Frank N, van Bokhoven Hans, Jacobs Joannes FM, Adema Gosse J, Hoogerbrugge Peter M, de Brouwer Arjan PM   +7 more
doaj   +5 more sources

Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature [PDF]

Insights into Imaging, 2023
Objectives To develop and validate an 18F-FDG PET/CT-based clinical-radiological-radiomics nomogram and evaluate its value in the diagnosis of MYCN amplification (MNA) in paediatric neuroblastoma (NB) patients.
Luo-Dan Qian, Shu-Xin Zhang, Si-Qi Li, Li-Juan Feng, Zi-Ang Zhou, Jun Liu, Ming-Yu Zhang, Ji-Gang Yang   +7 more
doaj   +2 more sources

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Cancer Cell International, 2017
Background MYCN gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the MYCN gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need ...
Zhi-Xia Yue, Cheng Huang, Chao Gao, Tian-Yu Xing, Shu-Guang Liu, Xing-Jun Li, Qian Zhao, Xi-Si Wang, Wen Zhao, Mei Jin, Xiao-Li Ma   +10 more
doaj   +2 more sources

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification [PDF]

Proceedings of the National Academy of Sciences, 2012
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis.
L. Valentijn, J. Koster, Franciska Haneveld, R. Aissa, P. V. van Sluis, M. Broekmans, J. Molenaar, J. van Nes, R. Versteeg   +8 more
semanticscholar   +3 more sources

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma [PDF]

Nature Communications, 2022
Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models.
Ling Tao, Mahmoud A. Mohammad, Giorgio Milazzo, Myrthala Moreno-Smith, Tajhal D. Patel, Barry Zorman, Andrew Badachhape, Blanca E. Hernandez, Amber B. Wolf, Zihua Zeng, Jennifer H. Foster, Sara Aloisi, Pavel Sumazin, Youli Zu, John Hicks, Ketan B. Ghaghada, Nagireddy Putluri, Giovanni Perini, Cristian Coarfa, Eveline Barbieri   +19 more
doaj   +5 more sources

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

Neoplasia: An International Journal for Oncology Research, 2013
Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate cancer, is a lethal tumor that most commonly arises in late stages of prostate adenocarcinoma (PCA) with predilection to metastasize to visceral organs.
Juan Miguel Mosquera, Himisha Beltran, Kyung Park, Theresa Y. MacDonald, Brian D. Robinson, Scott T. Tagawa, Sven Perner, Tarek A. Bismar, Andreas Erbersdobler, Rajiv Dhir, Joel B. Nelson, David M. Nanus, Mark A. Rubin   +12 more
doaj   +2 more sources